Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.33 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23722095 | 0.99 | MPO (0.42) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745569 | 0.90 | SOS1 (0.48) | MPOCNR1PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL23722157 | 0.89 | SOS1 (0.47) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745614 | 0.86 | MPO (0.44) | MPOSOS1F2PRSS1AGTR2 | |
| Hydrochloric Acid SCHEMBL23722090 | 0.85 | MPO (0.43) | MPOSOS1F2PRSS1AGTR2 | |
| SCHEMBL23745683 | 0.85 | CNR1 (0.38) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745576 | 0.85 | CNR1 (0.38) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745685 | 0.85 | CNR1 (0.38) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745690 | 0.85 | CNR1 (0.38) | MPOCNR1PDE4APDE4BPDE4C | |
| SCHEMBL23745479 | 0.84 | CNR1 (0.39) | MPOCNR1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | MPO 17/4885CNR1 1651/4885PDE4A 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.